Table 5.
Distribution of study participants according medical/medication history, Women Hospital-Hamad Medical Corporation, 2018
| Medical/ Medication history | Cases | Cases | Controls | p value | |
|---|---|---|---|---|---|
| Primary Infertility n = 43 (%) |
Secondary Infertility n = 93 (%) |
Infertility Total n = 136 (%) |
n = 272 (%) | ||
| Hypothyroidism: | 0.025* | ||||
| No | 35 (81.4) | 75 (80.6) | 110 (80.9) | 242 (89.0) | |
| Yes | 8 (18.6) | 18 (19.4) | 26 (19.1) | 30 (11.0) | |
| Hyperprolactinemia: | 0.001* | ||||
| No | 34 (79.1) | 78 (83.9) | 112 (82.4) | 255 (93.8) | |
| Yes | 9 (20.9) | 15 (16.1) | 24 (17.6) | 17 (6.2) | |
| Depression and/or other psychological disorders: | 0.002* | ||||
| No | 40 (93.0) | 88 (94.6) | 128 (94.1) | 270 (99.3) | |
| Yes | 3 (7.0) | 5 (5.4) | 8 (5.9) | 2 (0.7) | |
| Polycystic ovarian syndrome: | 0.001* | ||||
| No | 21 (48.8) | 43 (46.2) | 64 (47.1) | 220 (80.9) | |
| Yes | 22 (51.2) | 50 (53.8) | 72 (52.9) | 52 (19.1) | |
| Fibroid uterus: | 0.026* | ||||
| No | 37 (86.0) | 86 (92.5) | 123 (90.4) | 261 (96.0) | |
| Yes | 6 (14.0) | 7 (7.5) | 13 (19.6) | 11 (4.0) | |
| Appendectomy | 0.035* | ||||
| No | 41 (95.3) | 84 (94.3) | 125 (91.9) | 263 (96.7) | |
| Yes | 2 (4.7) | 9 (9.7) | 11 (8.3) | 9 (3.3) | |
| Prolonged steroid: | 0.050* | ||||
| No | 42 (97.7) | 84 (90.3) | 126(92.6) | 267 (98.2) | |
| Yes | 1 (2.3) | 9 (9.7) | 10 (7.4) | 5 (1.8) | |
| Hormonal therapy: | 0.001* | ||||
| No | 15 (34.9) | 19 (20.4) | 34 (25.0) | 260 (95.6) | |
| Yes | 28 (65.1) | 74 (79.6) | 102(75.0) | 12 (4.4) | |
| Prolonged high dose of NSAID: | 0.001* | ||||
| No | 40 (93.0) | 78 (83.9) | 118(86.8) | 261 (96.0) | |
| Yes | 3 (7.0) | 15 (16.1) | 18 (13.2) | 11 (4.0) | |
|
Anti-obesity (Xenical®,Meridia®): |
0.001* | ||||
| No | 42 (97.7) | 81 (87.1) | 123(90.4) | 267 (98.2) | |
| Yes | 1 (2.3) | 12 (12.9) | 13 (9.6) | 5 (1.8) | |
* p < 0.05
NSAID Non-Steroidal Anti Inflammatory Drugs
Xenical® is the trade name for Orlistat, Meridia® is the trade name for Sibutranine